Digoxin: Na+/K+ ATPase Pump Inhibitor for Heart Failure and Antiviral Research

Executive Summary: Digoxin is a potent cardiac glycoside that inhibits the Na+/K+-ATPase pump, increasing intracellular sodium and calcium concentrations and enhancing cardiac contractility (APExBIO, product page). It is used in research on heart failure, arrhythmias, and viral inhibition, including chikungunya virus (CHIKV) studies, where it shows dose-dependent antiviral effects in human and animal cell lines (Liu 2023, DOI). Solutions are highly soluble in DMSO (≥33.25 mg/mL), but insoluble in water or ethanol, and warrant prompt experimental use. APExBIO ensures high purity (>98.6%) and robust documentation (HPLC, NMR, MSDS), supporting reproducible workflows in cardiovascular and antiviral research models. Animal studies confirm improved cardiac output and reduced right atrial pressure upon intravenous administration (1–1.2 mg) in canine heart failure models (APExBIO, product page).

Biological Rationale

Digoxin is a well-characterized cardiac glycoside derived from Digitalis species. Its primary biological target is the Na+/K+-ATPase pump, which regulates the intracellular concentrations of sodium and potassium in excitable tissues such as cardiac myocytes (anti-trop2.com). Inhibition of this pump results in increased intracellular sodium, which indirectly raises intracellular calcium via the sodium-calcium exchanger. Elevated calcium enhances myocardial contractility, making Digoxin a valuable tool for dissecting cardiac physiology and pathophysiology (see also this article, which focuses on workflow applications; here, we emphasize mechanistic and antiviral findings).

Mechanism of Action of Digoxin

Digoxin binds specifically to the extracellular domain of the Na+/K+-ATPase alpha subunit, competitively inhibiting the exchange of intracellular Na⁺ for extracellular K⁺ (APExBIO). This leads to the following physiological effects:

• Increased intracellular Na⁺ reduces Na⁺/Ca²⁺ exchanger activity, elevating intracellular Ca²⁺.
• Elevated Ca²⁺ increases sarcoplasmic reticulum calcium load, promoting stronger and more efficient cardiac contractions.
• Digoxin also modulates autonomic tone, decreasing sympathetic outflow and increasing vagal activity, which can slow heart rate and AV conduction.
• In cellular models, Digoxin inhibits viral replication (e.g., CHIKV) by disrupting host ion homeostasis necessary for efficient viral entry and replication (DOI:10.1016/j.biopha.2025.118665).

Evidence & Benchmarks

• Digoxin increases cardiac output and reduces right atrial pressure in canine models of congestive heart failure after intravenous administration at 1–1.2 mg (APExBIO, product page).
• In human U-2 OS, primary synovial fibroblasts, and Vero cells, Digoxin inhibits chikungunya virus infection in a dose-dependent manner from 0.01 to 10 µM (Liu 2023, DOI).
• Digoxin demonstrates ≥33.25 mg/mL solubility in DMSO, but is insoluble in water and ethanol, dictating solvent selection for experimental protocols (APExBIO, product page).
• The compound is supplied at >98.6% purity, with batch-specific HPLC, NMR, and MSDS documentation, supporting reproducibility (APExBIO, product page).
• Digoxin's mechanistic role as a Na+/K+ ATPase pump inhibitor is validated across multiple research domains, including cardiovascular disease and antiviral studies (qpcrmaster.com; this article details recent animal model and viral inhibition evidence beyond prior summaries).

Applications, Limits & Misconceptions

Digoxin is a reference compound in cardiovascular disease research, especially for modeling heart failure and arrhythmias. It is also increasingly applied to virology, notably for CHIKV inhibition. However, certain boundaries and misconceptions must be clarified.

Common Pitfalls or Misconceptions

• Digoxin is not suitable for chronic storage in solution; aliquots should be freshly prepared in DMSO and used promptly to prevent degradation (APExBIO).
• It is insoluble in water or ethanol, so attempts to dissolve Digoxin in these solvents will lead to precipitation and unreliable dosing.
• Digoxin is not a general antiviral; its efficacy is best demonstrated for CHIKV and select other viruses, not for broad-spectrum antiviral applications (DOI).
• Effects observed in animal models (e.g., canine heart failure) may not translate directly to human dosing or disease states without careful pharmacokinetic and safety studies.
• Misidentification of purity or using non-validated sources can compromise reproducibility; APExBIO provides lot-specific QC data to mitigate this risk.

Workflow Integration & Parameters

Digoxin is supplied as a solid and should be stored at room temperature in a dry, protected environment (APExBIO, product page). For experimental use:

• Prepare fresh DMSO stock solutions at ≥33.25 mg/mL; dilute to working concentrations (e.g., 0.01-10 µM for cell culture assays).
• For cardiac tissue or animal models, titrate dosing based on species and route; in canine models, 1–1.2 mg IV has been benchmarked for acute studies.
• Confirm compound identity and purity using provided HPLC, NMR, and MSDS documentation for each batch.
• Dispose of unused solutions; do not freeze/rethaw DMSO stocks.

See the Digoxin (B7684) product page for full documentation and technical support.

Conclusion & Outlook

Digoxin remains a gold standard tool for dissecting cardiac contractility and arrhythmogenesis. Its expanding role in viral research, particularly for CHIKV inhibition, highlights its mechanistic versatility. APExBIO's high-purity, thoroughly documented Digoxin (SKU: B7684) enables precise, reproducible research workflows. For further reading, see this article for a deep-dive into novel mechanistic insights; the present article adds data on workflow parameters and antiviral benchmarks. Continued advances in pharmacokinetic profiling and disease modeling will further inform Digoxin's experimental applications (Liu 2023, DOI).